Close Menu

QuantumDx

The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.

The firm also announced the appointment of new board members as it heads toward commercialization of a portable MDx platform.

The test will be developed in Global Good labs and ported onto QuantuMDx's handheld molecular platform.

Q-POC

The funding will be used to further develop a 20-minute tuberculosis detection assay and drug susceptibility test using the firm's handheld Q-POC microfluidic PCR system.

QuantuMDx says its low-cost, handheld device will be able to quickly diagnose patients, as the Guardian reports.

QuantuMDx will use Scienion's ultra-low-volume liquid handling technologies in its Q-Poc handheld molecular diagnostic device.

The California Institute of Technology has been awarded

NEW YORK (GenomeWeb) – The Foundation for Innovative New Diagnostics is collaborating with multiple firms to accelerate the development of low-cost molecular diagnostics for tuberculosis and drug resistance determination, the non-profit organization said today.

NEW YORK (GenomeWeb) – QuantuMDx, a Newcastle, UK-based molecular diagnostics company, last week announced that it had successfully completed the development of its Q-POC handheld testing device.

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.